ZYME Estados financieros: Análisis de Zymeworks Inc AI

Inicio

Acciones

ZYME

Finanzas

ZYME Financiero

Zymeworks Inc

$25.8

-0.53%

$-0.14

Al cierre: Apr 02, 16:00:00 GMT-4

$25.95

0.61%

$0.15

Mercado Posterior: Apr 02, 21:02:09 GMT-4

Visión general Pronóstico Ganando Dividendos Finanzas

Ingreso

Balance general

Flujo de efectivo

Anual

Trimestral

ZYME Ingreso

Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Ingresos	105	105	76	76	412	26
Crecimiento de los Ingresos (YoY)	38%	38%	0%	-82%	1,485%	-33%
Costo de los ingresos	--	--	--	--	--	--
Utilidad bruta	--	--	--	--	--	--
Venta, General y Administración	61	61	61	70	73	42
Investigación y Desarrollo	137	137	134	143	208	--
Gastos de Operación	198	198	196	214	282	242
Otras Ingresos (Gastos) No Operativos	0	0	0	0	0	0
Ingreso antes de impuestos	-79	-79	-116	-119	135	-212
Gasto por Impuesto a la Renta	1	1	6	0	10	0
Ingreso Neto	-81	-81	-122	-118	124	-211
Crecimiento de la Utilidad Neta	-34%	-34%	3%	-195%	-159%	17%
Acciones en Circulación (Diluidas)	75.33	75.4	75.84	68.86	65.2	51.6
Cambio de Acciones (YoY)	1%	-1%	10%	6%	26%	2%
EPS (Diluido)	-1.07	-1.07	-1.61	-1.72	1.91	-4.11
Crecimiento de EPS	-35%	-33%	-6%	-190%	-146%	15%
Flujo de efectivo libre	-35	-35	-113	-122	131	-205
Flujo de efectivo libre por acción	--	--	--	--	--	--
Margen bruto	--	--	--	--	--	--
Margen de operación	-87.61%	-87.61%	-156.57%	-181.57%	31.55%	-826.92%
Margen de beneficio	-77.14%	-77.14%	-160.52%	-155.26%	30.09%	-811.53%
Margen de flujo de caja libre	-33.33%	-33.33%	-148.68%	-160.52%	31.79%	-788.46%
EBITDA	-85	-85	-111	-128	137	-209
Margen de EBITDA	-80.95%	-80.95%	-146.05%	-168.42%	33.25%	-803.84%
D&A para EBITDA	7	7	8	10	7	6
EBIT	-92	-92	-119	-138	130	-215
Margen de EBIT	-87.61%	-87.61%	-156.57%	-181.57%	31.55%	-826.92%
Tasa de Impuesto Efectiva	-1.26%	-1.26%	-5.17%	0%	7.4%	0%

Estadísticas clave

Cierre Anterior

$25.94

Precio de apertura

$25.7

Rango del día

$25.7 - $26.71

Rango de 52 semanas

$9.03 - $28.49

Volumen

631.0K

Volumen promedio

768.3K

Rendimiento de dividendos

EPS (TTM)

-1.77

Cap. de mercado

$1.9B

¿Qué es ZYME?

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 264 full-time employees. The company went IPO on 2019-06-24. The firm is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The firm engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. The company has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The company is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The firm has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.



Características

Copiloto de IA para Acciones y Criptomonedas

Predicción de precios

Seguimiento de Recaudación de Fondos

Temas

Comparación de Criptomonedas

Recursos